Ratings by Raymond James (Danielle Brill)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/30/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/1/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2024 | uniQure BV | QURE | Upgrade | Strong Buy (Outperform) |
7.30 (47.76) |
554.25% | Details | |
| 11/20/2024 | argenx SE | ARGX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/20/2024 | Tectonic Therapeutics Inc. | TECX | New Coverage | Outperform (N/A) |
38.88 (30.59) |
-21.32% | Details | |
| 11/18/2024 | Regenxbio Inc. | RGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2024 | Disc Medicine | IRON | Upgrade | Strong Buy (Outperform) |
47.13 (71.31) |
51.3% | Details | |
| 10/31/2024 | Agios Pharma | AGIO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2024 | argenx SE | ARGX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/10/2024 | Agios Pharma | AGIO | New Coverage | Outperform (N/A) |
40.89 (35.95) |
-12.08% | Details | |
| 10/10/2024 | uniQure BV | QURE | New Coverage | Outperform (N/A) |
5.61 (7.30) |
30.12% | Details | |
| 10/10/2024 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
39.42 (55.48) |
40.74% | Details | |
| 10/10/2024 | PTC Therapeutics | PTCT | New Coverage | Market Perform (N/A) |
39.94 (82.92) |
107.61% | Details | |
| 10/10/2024 | Vertex | VRTX | New Coverage | Market Perform (N/A) |
467.97 (475.26) |
1.56% | Details | |
| 10/10/2024 | Immunovant | IMVT | New Coverage | Outperform (N/A) |
30.02 (37.92) |
26.32% | Details | |
| 10/10/2024 | Sarepta Therapeutics | SRPT | New Coverage | Outperform (N/A) |
117.99 (17.29) |
-85.35% | Details | |
| 10/10/2024 | Denali Therapeutics Inc. | DNLI | New Coverage | Market Perform (N/A) |
26.52 (24.96) |
-5.88% | Details | |
| 10/10/2024 | Sage Therapeutics | SAGE | New Coverage | Market Perform (N/A) |
6.49 (8.68) |
33.74% | Details | |
| 10/10/2024 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
111.62 (167.86) |
50.39% | Details | |
| 10/10/2024 | argenx SE | ARGX | New Coverage | Strong Buy (N/A) |
520.52 (874.37) |
67.98% | Details | |
| 10/10/2024 | Acadia Pharmaceuticals | ACAD | New Coverage | Market Perform (N/A) |
14.59 (23.31) |
59.77% | Details | |
| 10/10/2024 | Biogen | BIIB | New Coverage | Market Perform (N/A) |
185.76 (199.54) |
7.42% | Details | |
| 10/10/2024 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Outperform (N/A) |
33.60 (34.76) |
3.45% | Details | |
| 10/10/2024 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Outperform (N/A) |
69.80 (57.13) |
-18.15% | Details | |
| 8/8/2024 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2024 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/20/2024 | PTC Therapeutics | PTCT | Upgrade | Market Perform (Underperform) |
33.10 (82.92) |
150.51% | Details | |
| 4/30/2024 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/17/2024 | Sage Therapeutics | SAGE | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/1/2024 | Disc Medicine | IRON | Downgrade | Outperform (Strong Buy) |
62.26 (71.31) |
14.54% | Details | |
| 3/20/2024 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
28.43 (46.23) |
62.61% | Details | |
| 2/22/2024 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/7/2023 | Biogen | BIIB | Upgrade | Outperform (Market Perform) |
233.87 (199.54) |
-14.68% | Details | |
| 10/31/2023 | Neurocrine Bio. | NBIX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/13/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/28/2023 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Market Perform (N/A) |
90.37 (57.13) |
-36.78% | Details | |
| 9/26/2023 | Immunovant | IMVT | Upgrade | Outperform (N/A) |
20.28 (37.92) |
86.98% | Details | |
| 9/15/2023 | PTC Therapeutics | PTCT | Downgrade | Underperform (Outperform) |
37.39 (82.92) |
121.77% | Details | |
| 8/4/2023 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/26/2023 | FibroGen | FGEN | Downgrade | Market Perform (Outperform) |
16.05 (9.71) |
-39.5% | Details | |
| 6/9/2023 | Disc Medicine | IRON | Upgrade | Strong Buy (Outperform) |
39.47 (71.31) |
80.67% | Details | |
| 5/24/2023 | Sarepta Therapeutics | SRPT | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/17/2023 | Disc Medicine | IRON | New Coverage | Outperform (N/A) |
32.00 (71.31) |
122.84% | Details | |
| 3/14/2023 | Biogen | BIIB | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/26/2023 | FibroGen | FGEN | Upgrade | Outperform (Market Perform) |
20.33 (16.05) |
-21.05% | Details | |
| 11/2/2022 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2022 | Neurocrine Bio. | NBIX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/19/2022 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
34.76 (55.48) |
59.61% | Details | |
| 7/29/2022 | Sarepta Therapeutics | SRPT | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 6/24/2022 | Sarepta Therapeutics | SRPT | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 6/21/2022 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/15/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/1/2022 | Sage Therapeutics | SAGE | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 5/16/2022 | Passage Bio Inc. | PASG | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2022 | Neurocrine Bio. | NBIX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/20/2022 | argenx SE | ARGX | Maintain | Strong Buy (Strong Buy) |
|
Details | ||
| 3/22/2022 | argenx SE | ARGX | Maintain | Strong Buy (Strong Buy) |
|
Details | ||
| 3/10/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/3/2022 | Passage Bio Inc. | PASG | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2022 | Sarepta Therapeutics | SRPT | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/28/2022 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/24/2022 | Global Blood Therapeutics | GBT | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/18/2022 | Agios Pharma | AGIO | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/16/2022 | Sage Therapeutics | SAGE | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/11/2022 | Passage Bio Inc. | PASG | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/11/2022 | Neurocrine Bio. | NBIX | Maintain | Outperform (Outperform) |
|
Details | ||
| 12/20/2021 | argenx SE | ARGX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/16/2021 | uniQure BV | QURE | Downgrade | Outperform (Strong Buy) |
28.75 (47.76) |
66.12% | Details | |
| 12/10/2021 | Denali Therapeutics Inc. | DNLI | New Coverage | Market Perform (N/A) |
46.16 (24.96) |
-45.93% | Details | |
| 12/10/2021 | Biogen | BIIB | New Coverage | Market Perform (N/A) |
234.72 (199.54) |
-14.99% | Details | |
| 11/4/2021 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Outperform (N/A) |
41.75 (34.76) |
-16.74% | Details | |
| 10/29/2021 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2021 | argenx SE | ARGX | Upgrade | Strong Buy (Outperform) |
279.58 (874.37) |
212.74% | Details | |
| 10/4/2021 | Acceleron Pharma | XLRN | Downgrade | Market Perform (Strong Buy) |
174.35 (178.75) |
2.52% | Details | |
| 8/20/2021 | FibroGen | FGEN | Upgrade | Market Perform (Underperform) |
12.06 (9.71) |
-19.49% | Details | |
| 7/1/2021 | Vertex | VRTX | New Coverage | Market Perform (N/A) |
196.78 (475.26) |
141.52% | Details | |
| 7/1/2021 | Agios Pharma | AGIO | New Coverage | Market Perform (N/A) |
53.53 (40.89) |
-23.61% | Details | |
| 7/1/2021 | Passage Bio Inc. | PASG | New Coverage | Outperform (N/A) |
13.12 (6.26) |
-52.29% | Details | |
| 6/22/2021 | Global Blood Therapeutics | GBT | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/1/2021 | Immunovant | IMVT | Downgrade | Market Perform (Outperform) |
15.16 (37.92) |
150.13% | Details | |
| 5/6/2021 | uniQure BV | QURE | Maintain | Strong Buy (N/A) |
|
Details | ||
| 4/5/2021 | Acadia Pharmaceuticals | ACAD | Downgrade | Market Perform (Outperform) |
25.59 (23.31) |
-8.91% | Details | |
| 3/9/2021 | Acadia Pharmaceuticals | ACAD | Downgrade | Outperform (Strong Buy) |
45.78 (25.59) |
-44.1% | Details | |
| 2/2/2021 | Immunovant | IMVT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/2/2021 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
109.75 (167.86) |
52.95% | Details | |
| 2/1/2021 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/19/2021 | Acceleron Pharma | XLRN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/8/2021 | Sarepta Therapeutics | SRPT | Downgrade | Market Perform (Outperform) |
166.45 (17.29) |
-89.61% | Details | |
| 12/31/2020 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2020 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/16/2020 | Acadia Pharmaceuticals | ACAD | Upgrade | Strong Buy (Outperform) |
50.61 (45.78) |
-9.54% | Details | |
| 11/6/2020 | Global Blood Therapeutics | GBT | Downgrade | Market Perform (Outperform) |
61.88 (68.49) |
10.68% | Details | |
| 10/26/2020 | FibroGen | FGEN | New Coverage | Underperform (N/A) |
42.60 (9.71) |
-77.21% | Details | |
| 8/25/2020 | Immunovant | IMVT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/25/2020 | Zogenix, Inc. | ZGNX | New Coverage | Market Perform (N/A) |
22.94 (26.68) |
16.3% | Details | |
| 8/25/2020 | Sarepta Therapeutics | SRPT | New Coverage | Outperform (N/A) |
141.94 (17.29) |
-87.82% | Details | |
| 8/25/2020 | uniQure BV | QURE | New Coverage | Strong Buy (N/A) |
38.52 (28.75) |
-25.36% | Details | |
| 8/25/2020 | PTC Therapeutics | PTCT | New Coverage | Outperform (N/A) |
48.58 (82.92) |
70.69% | Details | |
| 8/25/2020 | Momenta Pharmaceuticals | MNTA | New Coverage | Market Perform (N/A) |
52.32 (52.48) |
0.31% | Details | |
| 8/25/2020 | GW Pharma | GWPH | New Coverage | Market Perform (N/A) |
109.31 (218.96) |
100.31% | Details | |
| 8/25/2020 | Global Blood Therapeutics | GBT | New Coverage | Outperform (N/A) |
65.76 (68.49) |
4.15% | Details | |
| 8/25/2020 | Immunovant | IMVT | New Coverage | Outperform (N/A) |
32.59 (15.16) |
-53.48% | Details | |
| 8/25/2020 | argenx SE | ARGX | New Coverage | Outperform (N/A) |
236.18 (279.58) |
18.38% | Details | |
| 8/25/2020 | Acadia Pharmaceuticals | ACAD | New Coverage | Outperform (N/A) |
38.32 (23.31) |
-39.17% | Details |
